14:00 CET

Webcast - Year-end Report 2020

Oncopeptides will also hold a webcast Thursday February 18, 2021 at 14:00 (CET) when the Year-end Report 2020 and an operational update will be presented by CEO Marty J Duvall, CMO Klaas Bakker and CFO Anders Martin-Löf.

The conference call will also be streamed via the link: https://tv.streamfabriken.com/oncopeptides-q4-2020

Phone numbers for participants from:
Sweden: +46 8 566 426 95
Europe: +44 3333 009 030
USA: +1 833 526 83 47

Upcoming events

Webcast - CHMP issues a positive opinion recommending full approval of Oncopeptides Pepaxti in EU

11:00 CET

June 23, 2022, the European Medicines Agency´s (EMA) Committee for Medicinal Products for Human Use (CHMP), has unanimously adopted a positive opinion recommending a full marketing authorization approval (MAA) of Pepaxti® (melphalan flufenamide, also called melflufen) in EU.

Annual General Meeting 2022

The Annual General Meeting in Oncopeptides AB (publ) will be held on Tuesday June 28, 2022, (changed from May 19, 2022) in Stockholm, Sweden. Due to the extraordinary situation resulting from the covid-19 pandemic, Oncopeptides’ Annual General Meeting will be carried out through advance voting (postal voting) pursuant to temporary legislation. No meeting with the possibility to attend in person or to be represented by a proxy will take place. Hence, the Annual General Meeting will be held without physical presence.

Silent Period

-

Silent Period

-

Silent Period

-

Year-end report 2022

08:00 CET